z-logo
open-access-imgOpen Access
Mitochondrial network structure homeostasis and cell death
Author(s) -
Xie Longlong,
Shi Feng,
Tan Zheqiong,
Li Yueshuo,
Bode Ann M.,
Cao Ya
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13830
Subject(s) - necroptosis , mfn1 , mitochondrial fission , microbiology and biotechnology , dnm1l , mitochondrial fusion , programmed cell death , biology , mitochondrion , autophagy , dnaja3 , mitophagy , apoptosis , mitochondrial dna , genetics , gene
Mitochondria are the major cellular energy‐producing organelles and intracellular source of reactive oxygen species. These organelles are responsible for driving cell life and death through mitochondrial network structure homeostasis, which is determined by a balance of fission and fusion. Recent advances revealed that a number of components of the fission and fusion machinery, including dynamin‐related protein 1 (Drp1), mitofusin1/2 (Mfn1/2) and Optic atrophy 1 ( OPA 1), that have been implicated in mitochondrial shape changes are indispensible for autophagy, apoptosis and necroptosis. Drp1 is the main regulator of mitochondrial fission and has become a key point of contention. The controversy focuses on whether Drp1 is directly involved in the regulation of cell death and, if involved, whether is it a stimulator or a negative regulator of cell death. Here, we examine the relevance of the homeostasis of the mitochondrial network structure in 3 different types of cell death, including autophagy, apoptosis and necroptosis. Furthermore, a variety of cancers often exhibit a fragmented mitochondrial phenotype. Thus, the fragmented ratio can reflect tumor progression that predicts prognosis and therapeutic response. In addition, we investigate whether the targeting of the mitochondrial fission protein Drp1 could be a novel therapeutic approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here